Market Place
Sourcing Support
Aptar Named Among Top 50 of ‘World’s Top Companies for Women 2024’
13 Nov 2024 //
BUSINESSWIRE
US-based AptarGroup breaks ground for new pharma plant in Taloja
13 Nov 2024 //
ECONOMICSTIMES
Aptar Pharma Signs Deal with Cambridge Healthcare for Inhaler
07 Nov 2024 //
BUSINESSWIRE
Aptar Awarded Contract To Advance Sterilization Technology
22 Oct 2024 //
BUSINESSWIRE
Aptar CSP’s N-Sorb Accepted to FDA’s Emerging Tech Program
14 Oct 2024 //
CONTRACTPHARMA
Aptar Announces $500M Share Repurchase Authorization
10 Oct 2024 //
BUSINESSWIRE
Aptar Pharma Acquires SipNose Device Technology Assets
09 Oct 2024 //
BUSINESSWIRE
Aptar Pharma Celebrates North America Capacity Expansion
24 Sep 2024 //
BUSINESSWIRE
Aptar`s N-Sorb Accepted To FDA`s Emerging Technology Program
23 Sep 2024 //
BUSINESSWIRE
Aptar Pharma And Pulmotree To Develop Non-Propellant Liquid Inhaler Platform
10 Sep 2024 //
INDIANPHARMAPOST
Aptar Pharma Partners With Pulmotree For Kolibri Inhaler Platform
09 Sep 2024 //
BUSINESSWIRE
Aptar’s nasal unidose system delivers FDA-approved neffy
19 Aug 2024 //
INDIANPHARMAPOST
Aptar Reports Second Quarter 2024 Results
25 Jul 2024 //
BUSINESSWIRE
Aptar Increases Quarterly Dividend By Nearly 10% Due To Strong Performance
11 Jul 2024 //
BUSINESSWIRE
Aptar Releases 2023 Corporate Sustainability / ESG Report
30 May 2024 //
BUSINESSWIRE
Aptar, Iona Mind Partner For Digital Mental Health Support
29 May 2024 //
BUSINESSWIRE
Aptar Receives Platinum Rating from EcoVadis for the Fourth Consecutive Year
21 May 2024 //
BUSINESSWIRE
Aptar Closures introduces new e-Commerce disc top closure for beauty, personal a
08 May 2024 //
INDINPHARMAPOST
Aptar Reports First Quarter 2024 Results
25 Apr 2024 //
BUSINESSWIRE
Aptar Declares Quarterly Dividend
11 Apr 2024 //
BUSINESSWIRE
Aptar Pharma’s Airless+ system delivers China NMPA approved rosacea treatment
11 Apr 2024 //
PHARMABIZ
Aptar Pharma Continues Global Expansion with North America Capacity Extension
14 Mar 2024 //
BUSINESSWIRE
Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies
29 Feb 2024 //
BUSINESSWIRE
Aptar Signs Enterprise Agreement with Biogen
09 Feb 2024 //
BUSINESSWIRE
Aptar Reports Fourth Quarter and Annual 2023 Results
08 Feb 2024 //
BUSINESSWIRE
Aptar Declares Quarterly Dividend and Announces 2024 Annual Meeting Details
18 Jan 2024 //
BUSINESSWIRE
Aptar to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Aptar Announces 2024 Quarterly Conference Call Dates
02 Jan 2024 //
BUSINESSWIRE
Aptar Pharms opens new production facility at Taloja, Mumbai
10 Dec 2023 //
INDIAN PHARMA POST
Aptar Awarded Contract to Study Opportunities for Global Warming Propellants
04 Dec 2023 //
BUSINESSWIRE
Aptar Named Among the 100 Best Corporate Citizens for Third Consecutive Year
18 Oct 2023 //
BUSINESSWIRE
Aptar Declares Quarterly Dividend
12 Oct 2023 //
BUSINESSWIRE
Aptar Appoints Veteran Sarah Glickman to its Board of Directors
05 Sep 2023 //
BUSINESSWIRE
Aptar Announces 2023 Investor Day
24 Aug 2023 //
BUSINESSWIRE
Aptar Reports Second Quarter 2023 Results
27 Jul 2023 //
BUSINESSWIRE
Aptar Announces Quarterly Dividend Increase of 7.9%
13 Jul 2023 //
BUSINESSWIRE
Aptar Mourns Passing of Ervin J. LeCoque, First CEO and Board Chairman
26 Jun 2023 //
BUSINESSWIRE
Aptar Named One of America’s Climate Leaders by USA Today
24 May 2023 //
BUSINESSWIRE
Aptar Named a CDP Supplier Engagement Leader for the Third Consecutive Year
23 Mar 2023 //
BUSINESSWIRE
Aptar Named One of Barron’s 100 Most Sustainable Companies in the U.S.
08 Mar 2023 //
BUSINESSWIRE
Aptar Appoints Julie Xing to its Board of Directors
01 Mar 2023 //
BUSINESSWIRE
Aptar Reports Fourth Quarter and Annual 2022 Results
16 Feb 2023 //
BUSINESSWIRE
Aptar Pharma Launches First Metal-Free Nasal Spray Pump
02 Feb 2023 //
CONTRACT PHARMA
Aptar creates metal-free nasal spray pump to boost recyclability
31 Jan 2023 //
FIERCE PHARMA
Aptar Pharma Launches First Metal-Free Nasal Spray Pump
30 Jan 2023 //
BUSINESSWIRE
Aptar to Present at 41st Annual J.P. Morgan Healthcare Conference
22 Dec 2022 //
BUSINESSWIRE
Aptar Pharma multi-dose device delivers approved human anti-COVID nasal spray
20 Dec 2022 //
EXPRESSPHARMA
Aptar in Top 15 of America’s Most Responsible Companies 2023 by Newsweek
15 Dec 2022 //
BUSINESSWIRE
Aptar Announces the Realignment of Two of its Business Reporting Segments
12 Dec 2022 //
BUSINESSWIRE
TFF to Collaborate with Aptar for Intranasal Delivery of Dry Powder Vaccines
03 Nov 2022 //
GLOBENEWSWIRE
Aptar Reports Third Quarter 2022 Results
27 Oct 2022 //
BUSINESSWIRE
Aptar and Chiesi Sign Contract to bring Best Disease Management Platform
18 Oct 2022 //
BUSINESSWIRE
Aptar Declares Quarterly Dividend
13 Oct 2022 //
BUSINESSWIRE
Aptar launches digital disease management platform
12 Oct 2022 //
PHARMAPHORUM
Aptar Digital Health Launches New Digital Disease Management Platform
11 Oct 2022 //
PHARMIWEB
Aptar Expands Pharmaceutical Services
29 Sep 2022 //
CONTRACTPHARMA
Aptar Expands Pharma Services; Announces Collaboration Between Aptar & Fluidda
22 Sep 2022 //
BUSINESSWIRE
Aptar Appoints Matthew L. Trerotola to its Board of Directors
12 Sep 2022 //
BUSINESSWIRE
Aptar Pharma Acquires Metaphase Design Group
06 Sep 2022 //
CONTRACTPHARMA
